Reply to Blot et al. and to Inoue et al..pdf (504.07 kB)
Download file

Reply to Blot et al. and to Inoue et al.

Download (504.07 kB)

We thank Blot and colleagues for their interest in our article and for raising an important question regarding the suitability of IL-6 as a therapeutic target in coronavirus disease (COVID-19).

In their correspondence, Blot and colleagues provide data on IL-6 levels measured in patients with a diagnosis of COVID-19 versus non–COVID-19 pneumonia. Although we believe the data presented by Blot and colleagues are valid, we suggest that the IL-6 levels depicted are, by virtue of sample timing, processing methodology, and patient severity of disease, not comparable to ours and should be interpreted in context.

History

Comments

The original article is available at https://www.atsjournals.org/

Published Citation

McElvaney OJ, McEvoy NL, McElvaney NG, Curley GF. Reply to Blot et al. and to Inoue et al. Am J Respir Crit Care Med. 2021;203(1):141-142

Publication Date

21 September 2020

PubMed ID

32955924

Department/Unit

  • Anaesthetics and Critical Care
  • Beaumont Hospital
  • Medicine

Publisher

American Thoracic Society

Version

  • Published Version (Version of Record)